Browse All

Current Filters

CLEAR FILTER x

TITLE

Design and Baseline characteristic of Phase II clinical trial of allogeneic bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease

A Caveat in Identifying a Suitable Reference for Quantitative Susceptibility Mapping in Parkinson’s Disease